论文部分内容阅读
目的 研究CA125和NSE在肺癌诊断和判断预后中的作用。方法 用免疫学方法测定肺癌和BLD病人血清中CA125、NSE含量并进行分析。结果 肺癌患者血清CA125、NSE水平显著高于BLD,分别为CA125:37.2±7.67NG/ML比 14.18±2.58NG/ML(P<0.01);NSE:4.54±1.36NG/ML比2.74±0.8NG/ML(P<0.05)。肺癌患者CA125、NSE检测阳性率明显高于BLD,且随肿瘤的分型、分期不同而不同。联合检测NSE+CA125敏感性为78％,高于单独检测CA125和NSE的敏感性。结论 测定肺癌病人血清中CA125、NSE可作为辅助诊断和判断预后的指标,联合检测CA125和NSE可提高肺癌诊断的敏感性。
Objective To study the role of CA125 and NSE in the diagnosis and prognosis of lung cancer. Methods The serum levels of CA125 and NSE in patients with lung cancer and BLD were measured by immunological methods and analyzed. Results The serum levels of CA125 and NSE in lung cancer patients were significantly higher than those in BLD, which were CA125: 37.2±7.67NG/ML compared with 14.18±2.58NG/ML (P<0.01); NSE:4.54±1.36NG/ML ratio was 2.74±0.8NG/N ML (P<0.05). The positive rate of CA125 and NSE in patients with lung cancer was significantly higher than that in BLD, and it varied with the tumor type and stage. The combined detection of NSE+CA125 had a sensitivity of 78%, which was higher than the sensitivity of detecting CA125 and NSE alone. Conclusion The determination of serum CA125 and NSE in lung cancer patients can be used as an auxiliary diagnosis and prognosis index. Combined detection of CA125 and NSE can improve the sensitivity of lung cancer diagnosis.